Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

This study has been terminated.
(Terminated due to difficulty in accruing patients)
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Washington Hospital Center
ClinicalTrials.gov Identifier:
NCT00810017
First received: December 16, 2008
Last updated: November 4, 2011
Last verified: November 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2010
  Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)